Anti-CD138/Syndecan-1 Rabbit Monoclonal Antibody for WB - P18827

Core Product Specifications and Parameters

Biological Background: CD138/Syndecan-1 Function and Localization

• Syndecan-1 is a cell surface proteoglycan that contains both heparan sulfate and chondroitin sulfate chains, linking the cytoskeleton to the interstitial matrix.
• It plays a role in regulating exosome biogenesis by interacting with SDCBP and PDCD6IP. Related references: PMID:22660413
• Syndecan-1 can induce its own expression in dental mesenchymal cells and neighboring dental epithelial cells through an MSX1-mediated pathway.
• The protein is found in membrane, secreted, and extracellular exosome compartments.
• Tissue-specific expression has been detected in placenta and fibroblasts.
• Post-translational modifications include phosphorylation and attachment of heparan sulfate and chondroitin sulfate glycosaminoglycan chains.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (amino acids 23-254), suggesting the antibody recognizes an epitope within this region; consider using a recombinant fragment as a positive control.
• For Western blotting, the predicted band is around 32 kDa, but extensive glycosylation may cause migration at higher molecular weights; validate under reducing and non-reducing conditions.
• This antibody has been tested on human, mouse, and rat samples; verify reactivity in your specific tissue or cell line before large-scale experiments.
• For immunohistochemistry (IHC-P) and immunofluorescence (IF-P), optimize fixation and antigen retrieval methods based on sample type.

CamelBio: Your One-Stop Sourcing Bridge

As a dedicated IVD raw-material partner, CamelBio streamlines procurement of validated antibodies like this anti-CD138/Syndecan-1 clone, supporting cell adhesion, matrix biology, and oncology research. Our one-stop platform offers optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and customized sourcing for rare targets, helping diagnostic manufacturers accelerate development from concept to clinic.